Genus PLC
27 November 2007

Genus plc

('Genus' or the 'Company')

Animalcare Limited Disposal

Genus, a world leading animal genetics company, is pleased to announce that it has entered into an agreement to dispose of Animalcare Limited ('Animalcare'), its non-core veterinary pharmaceutical business, to Ritchey plc for a total cash consideration of Â£14m, including a deferred element of Â£0.6m. The proceeds of the disposal will be used to reduce debt.

The transaction is subject to financing which Ritchey plc plans to achieve through a fundraising upon its admission to the AIM market. It is expected that the transaction will complete on 10 January 2008. Payment of the Â£0.6m of deferred consideration is conditional upon a manufacturing contract being set up for a new product, currently under development.

For the year ended 30 June 2007, Animalcare generated an adjusted operating profit of Â£1.6m. As at 30 June 2007 it had net assets of Â£6.7m.

For further information, please contact:
Genus plc Tel: 01256 345970
Richard Wood, Chief Executive
Martin Boden, Finance Director

Landsbanki Securities (UK) Limited Tel: 020 7426 9000
Financial Adviser & Joint Broker
Shaun Dobson

Buchanan Communications Tel: 020 7466 5000
Charles Ryland / Suzanne Brocks

About Genus

Genus creates and sells added value products for livestock farming and food producers by creating advances to animal breeding through biotechnology. Its non-Genetically Modified Organism (GMO) technology is applicable across all livestock species but is only commercialised by Genus in the bovine and porcine farming sectors.

Genus' worldwide sales are made in seventy countries under the trade marks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production. Customers use Genus genetics on their herds to produce offspring with greater production efficiency, milk and meat output and quality and use these to supply the global dairy and meat supply chain.

Genus' competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and the Group's global production and distribution network.

Headquartered in Basingstoke, England, Genus companies operate in 30 countries on five continents, with research laboratories located in Madison, USA.

This information is provided by RNS
The company news service from the London Stock Exchange